Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is for patients with breast cancer that has spread to other tissues and organs.
The purpose of this study is to identify patients who may respond favorably to certain types
of hormonal therapy. Researchers will study your tumor, which was removed during your breast
surgery. They will look for the presence or absence of Androgen (AR) receptors. These tests
are for research purposes only. They will not affect the treatment of your breast cancer. The
presence or absence of Androgen receptors on the tumor does not alter the therapy that is
offered to patients. Recent evidence suggests that AR+ tumors are more likely to be destroyed
when treated with androgen drugs. We will ask about 35 ER-/PR- breast cancer patients from
Legacy Health System to be in this study. All tests and procedures are done as an outpatient
in the doctor's office, a clinic, or at the hospital. The study drug that will be used in
this trial is Androxy®, a synthetic androgen hormone. Androgens have been shown to inhibit
the growth of some breast cancer cells. Arimidex is an aromatase inhibitor that will be used
in conjunction with Androxy to inhibit the in vivo production of estrogen. It is hoped that
the combination of these two drugs will inhibit the growth of your tumor and possibly cause
it to shrink.